Acne and Mood: Impact of Treatment on Depression, Anxiety, and Sexual Function
Withdrawn before enrolling
Conditions studied: Acne Vulgaris
In brief
This study seeks to examine if there is any relationship between spironolactone use prescribed for acne vulgaris and depression, anxiety, and/or sexual function.
Key facts
- Study ID
- NCT03921476
- Run by
- Northwestern University
- People needed
- 0
- Starts
- 2020-07-01
- Expected to finish
- 2020-12-31
- Last updated by the study team
- 2020-10-09
Who can join
Age: 18 and older, up to 65. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Female subjects between 18 and 65 years of age currently taking spironolactone for a diagnosis of acne vulgaris
- OR
- Female subjects between 18 and 65 years of age currently taking oral antibiotics for a diagnosis of acne vulgaris
- AND Subjects able to complete an online survey in English
You may not qualify if…
- Subjects less than 18 years of age or older than 65 years of age Subjects that have ever been diagnosed with any mood disorder by a clinician prior to starting spironolactone (history of mood disorder or current mood disorder) Subjects taking hormonal contraception (including but not limited to oral contraceptive pills) for a duration of less than 6 months Subjects that have ever been diagnosed with any type of sexual dysfunction prior to starting spironolactone Subjects not able to complete an online survey in English Subjects taking oral isotretinoin for a diagnosis of acne Subjects that are currently pregnant
Where it is running
- Northwestern University — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.